They decrease inflammatory markers, lower LDL cholesterol and triglycerides, and have been shown to reduce major adverse cardiovascular events
Possible effects include nausea, reflux, constipation, or fatigue all of which are monitored closely and managed conservatively
Who Might Consider Reducore Instead of GLP-1s
However, a significant challenge in evaluating kidney outcomes lies in the inconsistent definitions of renal endpoints across studies, particularly regarding the thresholds for substantial eGFR decline, which vary from 30% to 57%
Wegovy, as an injection, is FDA approved to: Reduce excess body weight and maintain long-term weight reduction in: Adults with obesity and adolescents ages 12 years and older with obesity Adults with overweight plus at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol Treat a serious type of fatty liver disease called noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver scarring (stage F2 to F3 fibrosis) Lower the risk of major cardiovascular problems (such as heart attack, stroke, and heart-related death) in adults with established cardiovascular disease and obesity or overweight Contrave is FDA approved to: Reduce excess body weight and maintain long-term weight reduction in: Adults with obesity, defined as a body mass index (BMI) of 30 or higher Adults with a BMI of 27 or higher (overweight) plus at least one weight-related medical condition To recap, heres an at-a-glance comparison of FDA-approved uses for Wegovy vs
